Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and.

Similar presentations


Presentation on theme: "Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and."— Presentation transcript:

1 Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and problems W. Kurt Roth Red Cross Blood Transfusion Service Baden-Württemberg – Hessen, Institute Frankfurt am Main

2 Ro / BSD Hessen Institut für Transfusionsmedizin B19 / HAV-PCR: Testing Strategy  B19 and HAV PCR in parallel to HCV, HIV and HBV PCR  Aliquots of same extract as for HCV, HIV, HBV  Relevant for all blood components incl. platelets  Quantitative TaqMan PCR with internal control sequence  95% detection limit: 10 3 IU / ml (B19 and HAV)  B19 positive Pools  10 5 IU / ml: –Positive donation identified –Positive donation destroyed  B19 positive Pools < 10 5 IU / ml: –Positive donation not identified –All donations released (weak positive)

3 Ro / BSD Hessen Institut für Transfusionsmedizin Pool Deconstruction HCV, HBV, HIV, HAV, B19 PCR-only positives PCR and antibody positives 12 x 8 8 x 12 1 x 94 individual testing

4 Ro / BSD Hessen Institut für Transfusionsmedizin HAV / Parvo B19-PCR: Results April 2000 – May 2003: Sensitivity 10 5 IU / ml Rate of B19 positives at a sensitivity of 10 3 IU / ml: 1 : 700

5 Ro / BSD Hessen Institut für Transfusionsmedizin Parvo B19 Positives per Month Positives 10 5 (n) Total Frankf West

6 Ro / BSD Hessen Institut für Transfusionsmedizin Indications for B19-negative components  Parvo B19-negative (< 10 3 IU / ml) components upon specific written request; individual label: „Parvovirus B19 not detectable“ –Patients with BMT, SCT –B19 antibody-negative pregant women in the 1.and 2. trimenon –HIV patients –Additional risk groups e.g. transient aplastic crisis pure red cell aplasia  Parvo B19-negative and weak positive (> 10 3 ; < 10 5 IU / ml) components for all patients at no specific risk (no label); standard quality

7 Ro / BSD Hessen Institut für Transfusionsmedizin Parvo-B19 Seroconversion Medac IgM and IgG ELISA; Mikrogen IgG/IgM recomBlot


Download ppt "Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and."

Similar presentations


Ads by Google